# Marijuana Rescheduling Would Bring Some Immediate Changes, but Others Will Take Time
The recent push to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA) promises a mix of swift transformations and prolonged adjustments for the cannabis industry, researchers, and consumers.[1][2] On December 18, 2025, President Trump issued an executive order directing the Attorney General to expedite the ongoing DEA rulemaking process, prioritizing medical research and access to full-spectrum CBD products while navigating persistent federal hurdles.[1][2][4]
## The Current Status: Momentum Toward Schedule III
Marijuana’s placement in **Schedule I** has long classified it alongside substances like heroin, deeming it to have no accepted medical use and a high potential for abuse.[1][3] This stance originated decades ago but clashed with evolving science and state laws. In August 2023, the Department of Health and Human Services (HHS) recommended moving it to **Schedule III**, which recognizes moderate abuse potential and accepted medical uses, such as treating pain, nausea, and anorexia.[1][2]
The DEA proposed rescheduling in May 2024, drawing over 42,000 public comments and calls for a hearing originally set for January 21, 2025—but postponed amid appeals.[1] Trump’s executive order, titled “Increasing Medical Marijuana and Cannabidiol Research,” doesn’t alter laws directly but mandates the DOJ to finalize the process “in the most expeditious manner” under federal rules.[2][4][6] This signals strong administrative priority, yet completion hinges on hearings, potential court challenges, and rulemaking timelines that could stretch into 2026.[1][3]
## Immediate Changes Upon Rescheduling
If finalized, rescheduling to Schedule III would trigger several **immediate shifts**, easing long-standing burdens without full legalization.[2][3]
First, **tax relief for businesses** arrives right away. Section 280E of the Internal Revenue Code currently bars cannabis companies from deducting ordinary business expenses, inflating their federal tax rates to punitive levels—often over 70%—and fueling black-market competition.[3] Schedule III status lifts this restriction, allowing standard deductions and potentially lowering prices for state-legal operators.[3]
Second, **research barriers crumble quickly**. Schedule I demands DEA registration, special protocols, and storage for studies, stifling innovation.[2] Schedule III aligns marijuana with drugs like ketamine, streamlining federally funded trials on medical applications. The executive order boosts this by tasking HHS, FDA, NIH, and CMS with developing real-world evidence models for conditions like chronic pain.[2] Expect faster studies on efficacy, dosing, and full-spectrum products.
Third, **CBD access expands promptly**. The order pushes for “appropriate full-spectrum CBD products,” revising hemp definitions to clarify THC limits and ratios while curbing risky synthetics.[1][2] This aids patients in 40 states with medical programs, without touching recreational markets.[2]
Bankers and payment processors gain partial relief too, as reduced scheduling eases some compliance fears, though anti-money laundering rules persist.[2]
## Changes That Will Take Time: The Long Road Ahead
Not all benefits materialize overnight. **Regulatory and legal delays** loom large, as rescheduling invites lawsuits from prohibitionists and requires agency coordination.[1][3] The DEA hearing, already postponed, must resolve appeals before final rules issue—potentially months away.[1]
**FDA approvals remain a marathon**. Rescheduling doesn’t deem marijuana an “approved drug.” Each cannabis preparation or strain needs separate FDA green lights under the Food, Drug, and Cosmetic Act, involving years of safety, efficacy, and human trials costing hundreds of millions.[3] Adding cannabinoids to foods, cosmetics, or supplements still demands rigorous standards.[2] Nationwide prescriptions? Unlikely soon, as HHS noted no fast track exists.[3]
**Interstate commerce stays restricted**. Recreational use remains federally illegal, blocking cross-state sales even post-rescheduling.[2][4] State-legal businesses face ongoing federal conflicts, like zoning or licensing snags, until Congress acts—perhaps via hemp cannabinoid reforms hinted in the order.[2]
**Hemp-derived products** enter a gray zone. Recent laws capped total THC, muddying “hemp” vs. “marijuana” lines. The administration pledges a unified framework with THC-per-serving limits and CBD:THC ratios, but crafting this involves congressional input and could drag.[2]
Employer policies shift slowly too. While Schedule III softens zero-tolerance stances, drug testing and workplace rules vary by state and industry, demanding updated HR strategies.[4]
## Broader Implications for Industry and Patients
For the **cannabis sector**, immediate tax wins could inject billions in competitiveness, but sustained growth needs banking reforms and clearer hemp rules.[3] Patients benefit from research acceleration, yet access hinges on state programs—no federal dispensaries emerge.[2]
Advocates split: some hail progress, others push for descheduling to Schedule II or full removal.[1] Conflicts persist between federal reform and state laws, promising “regulatory confusion” in coming months.[1]
## Looking Forward
Rescheduling marks a pivotal step, blending quick wins like tax deductions and research ease with drawn-out battles over FDA nods and commerce.[1][2][3] As the Trump administration drives this via executive action, stakeholders must brace for hybrid timelines: some changes by mid-2026, others years out. Monitoring DEA updates remains key, as this could reshape a $30 billion industry while advancing medical insights—without upending recreational markets.[1][2]
(Word count: 812)
Original source: NPR News – Marijuana rescheduling would bring some immediate changes, but others will take time